Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at William Blair dropped their Q3 2017 earnings estimates for Charles River Laboratories International in a note issued to investors on Wednesday. William Blair analyst J. Kreger now anticipates that the medical research company will post earnings of $1.22 per share for the quarter, down from their previous forecast of $1.26. William Blair also issued estimates for Charles River Laboratories International’s FY2017 earnings at $5.11 EPS, FY2018 earnings at $5.63 EPS, FY2019 earnings at $6.21 EPS and FY2020 earnings at $6.86 EPS.

CRL has been the subject of a number of other reports. Credit Suisse Group reissued a “neutral” rating and set a $95.00 price objective (up from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. BidaskClub downgraded Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Jefferies Group LLC reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, June 14th. Finally, Citigroup Inc. reissued a “neutral” rating and set a $104.00 price objective (up from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $96.94.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/11/charles-river-laboratories-international-inc-to-post-q3-2017-earnings-of-1-22-per-share-william-blair-forecasts-crl.html.

Shares of Charles River Laboratories International (CRL) opened at 96.72 on Friday. Charles River Laboratories International has a 52 week low of $67.20 and a 52 week high of $102.32. The stock’s 50 day moving average is $99.87 and its 200-day moving average is $91.54. The stock has a market capitalization of $4.60 billion, a price-to-earnings ratio of 25.49 and a beta of 1.02.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. The firm had revenue of $469.13 million during the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The business’s revenue was up 8.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.20 earnings per share.

Several institutional investors have recently made changes to their positions in CRL. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after buying an additional 202 shares during the last quarter. Riverhead Capital Management LLC boosted its position in shares of Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after buying an additional 247 shares during the last quarter. Cambridge Advisors Inc. bought a new position in shares of Charles River Laboratories International during the second quarter valued at about $202,000. Advisor Partners LLC bought a new position in shares of Charles River Laboratories International during the second quarter valued at about $208,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Charles River Laboratories International during the second quarter valued at about $217,000. Institutional investors and hedge funds own 95.81% of the company’s stock.

In other Charles River Laboratories International news, Chairman James C. Foster sold 43,154 shares of Charles River Laboratories International stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total value of $4,315,400.00. Following the completion of the transaction, the chairman now directly owns 361,178 shares of the company’s stock, valued at approximately $36,117,800. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director George Massaro sold 3,830 shares of Charles River Laboratories International stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $100.81, for a total value of $386,102.30. Following the completion of the transaction, the director now directly owns 18,731 shares of the company’s stock, valued at $1,888,272.11. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,369 shares of company stock valued at $7,846,412. 2.20% of the stock is currently owned by corporate insiders.

Charles River Laboratories International declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, May 10th that authorizes the company to repurchase $150.00 million in shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.